Silicon Valley billionaires including Bezos, Thiel, Milner, and Altman are investing in cellular reprogramming technology to reverse aging. Life Biosciences has begun the first human trial, treating glaucoma patients with an experimental therapy that showed early promise with two of three patients experiencing vision improvements and no major side effects reported.
Silicon Valley billionaires including Bezos, Thiel, Milner, and Altman are investing in cellular reprogramming to reverse aging. Life Biosciences has begun the first human trial, injecting rejuvenation therapy into glaucoma patients, with two of three showing improved vision and no major side effects reported. Multiple biotech startups are racing to advance this longevity technique into human trials.
Silicon Valley billionaires including Bezos, Thiel, and Altman are investing in cellular reprogramming startups to reverse aging. Life Biosciences completed the first human trial, treating three glaucoma patients with an experimental eye injection and antibiotics; two showed vision improvements with no major side effects reported. The technique, proven effective in animals, could potentially address multiple age-related diseases if further clinical trials succeed.